Sustainability

Many of the biodiversity risks associated with pharmaceutical production occur beyond the direct operational control of pharmaceutical businesses, whic means that addressing them requires a collaborative, systemic approach to sustainability.

Galapagos scales back its cell therapy business to enhance efficiency and focus on transformative opportunities, impacting over 365 employees globally.

Merck invests $70 billion in US operations, launching a $3 billion manufacturing site in Virginia to enhance drug production and create jobs.

Johnson & Johnson plans to separate its orthopaedics business, creating DePuy Synthes, to enhance focus, innovation, and value for stakeholders.

The energy component—and cost—associated with artificial intelligence should not be overlooked in all the excitement.

JAMA study finds that redispensing oral anticancer drugs reduces approximately two-thirds of medication waste as healthcare stakeholders seek more sustainable practices.

A C-suite Q&A with Cristina Ortega Duran, President of Evinova.

Recognition of the business case for ESG in pharma is soaring.

Emerging technologies like digital twins offer supply chain efficiency solutions, allowing the industry to integrate sustainable practices while ensuring patient safety.

Life sciences executives who are confronted by too many choices in launching their environmental, social, and governance programs can leverage these two foundational tools to hone in on the set of issues, actions, and disclosures they should prioritize to create value.

While ESG is still in the early stages for pharma, many companies are moving forward with a need for compliance.

Examining efforts to boost women representation on company boards.

The validity of ESG-driven investment and reporting in healthcare.

Reaching new heights in sustainability a win-win for industry.

Pharma supply chains are no longer hidden beyond the reach of ESG agendas, making it important for companies to accelerate adoption of new manufacturing processes and environmental technology.

A prime opportunity for pharma to raise its strategic game in ESG.

Adam Carter discusses the causes and potential solutions to the pharma industry's sustainability issues.

How pharma companies can make sure their corporate strategy in ESG is appealing to younger generations—and aligns with the issues this large segment of sustainability investors care about most.

How principles of both can help companies navigate future storms.

Outlining the most important sustainability-related hurdles facing leading biopharma companies today—and current efforts underway to meet new expectations in advancing this strategic mandate.

Instead, incorporate ESG into your long-term business planning.

Rise in demand for sustainable practices forces industry to be more proactive.

New regulations set stage for updated ESG considerations.

Why purpose-driven firms are now more important than ever.